References
- Olszynski WP, Davison KS. Alendorate for the treatment of osteoporosis in men. Drug Eval 2008;9:491–8
- Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75–85
- Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80–100
- Porras GA, Holland DS, Gertz JB. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999;36:315–28
- Yun MH, Woo JS, Kwon KI. Bioequivalence and pharmacokinetics of 70 mg alendronate sodium tablets by measuring alendronate in plasma. Arch Pharm Res 2006;29:328–32
- Yun MH, Kwon KI. High-performance liquid chromatography method for determining alendronate sodium in human plasma by detecting fluorescence: application to a pharmacokinetic study in humans. J Pharm Biomed Anal 2006;40:168–72
- Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005;44:551–70
- Kang SH, Hwang JS, Park SJ, Kim KC. HPLC method validation and pharmacokinetic study of alendronate sodium in human urine with fluorescence detection. J Liq Chrom Relat Tech 2006;29:1589–600
- Gupta KV, Jain R, Sharma S, et al. Quantitative determination of alendronate in human urine. Int J Electrochem Sci 2012;7:569–87
- D’argenio ZD, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 1979;9:115–34
- Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
- DiPiro TJ, Spruill JW, Wade EW, et al. Two-compartment models. Concepts in clinical pharmacokinetics. 5th ed. Bethesda (MD): American Society of Health-System Pharmacists; 2010:73–5
- Cremers MLCS, Hogezand VR, Banffer D, et al. Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease. Osteoporos Int 2005;16:1727–30
- Mitchell DY, Eusebio RA, Dunlap LE, et al. Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res 1998;15:228–332
- DeWolf AM, Fragen RJ, Avram MJ, et al. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 2001;93:1205–9
- Swan KS, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318–29
- Kanis AJ, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. Osteoporos Int 1997;7:390–406
- Stepensky D, Kleinberg L, Hoffman A. Bone as an effect compartment: models for uptake and release of drugs. Clin Pharmacokinet 2003;42:863–81